ArticleScientific reports2026
Repurposing of natural products for spinocerebellar ataxia type 3 using integrated network pharmacology and in silico approaches.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Spinocerebellar ataxia type 3 (SCA3) is a progressive inherited neurodegenerative disorder characterized by impaired coordination and balance due to cerebellar ataxia. Currently, there are no Food and Drug Administration (FDA)-approved drugs or curative treatments for SCA3. This study aimed to uncover the potential therapeutic mechanism of natural products (NP or NPs) against SCA3 using an integrative computational strategy combining network pharmacology, molecular docking, molecular dynamics (MD) simulation, principal component analysis (PCA), free energy landscape (FEL), dynamic cross-correlation matrix (DCCM), and Molecular Mechanics/Poisson-Boltzmann Surface Area (MM/PBSA) calculations. A total of 4,986 SCA3-related targets were retrieved from the GeneCards database, and 696 unique NP-related targets were obtained from SwissTargetPrediction and SuperPred databases. Protein-protein interaction (PPI) network analysis revealed 239 overlapping targets. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis identified the MAPK signaling pathway (hsa04010) as a key mechanism involving 33 critical proteins, including AKT1, TP53, TNF, EGFR, RELA, and MAPK1. Among the screened compounds, crocin exhibited the highest binding affinities with AKT1 (- 9.5 kcal/mol) and TP53 (- 6.6 kcal/mol) in docking studies. Further validation through MD simulation, PCA, FEL, DCCM, and MM/PBSA analysis confirmed the stability and strong interaction of crocin with these targets. This study highlights crocin as a promising candidate for SCA3 therapy and provides a foundation for future experimental validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.